Shopping News / Articles
INVESTOR ALERT: Medpace Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Cla
8+ hour, 41+ min ago (126+ words) If you suffered substantial losses and wish to serve as lead plaintiff of the Medpace class action lawsuit, please provide your information here: You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via…...
LIR Life Sciences Announces Initiation of Phase 1 Macromolecule-Enabled Transdermal Delivery Develop
2+ day, 1+ hour ago (206+ words) Phase 1 of the program involves the solid-phase synthesis, purification, and analytical characterization of a highly active macromolecule delivery agent of relevance to LIR's transdermal delivery platform. Neuland will produce approximately 200 mg of an efficient transdermal agent as part of this…...
INTU Investigation: BFA Announces Intuit Investigation on behalf of Investors after 20% Stock Drop "
2+ day, 2+ hour ago (238+ words) BFA Law is investigating whether Intuit committed securities fraud relating to its representations about Turbo Tax's price positioning among DIY tax filers ahead of and during the 2026 tax season. NEW YORK--(BUSINESS WIRE)--$INTU #BFA--Leading securities law firm Bleichmar…...
Immunity Bio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with N
2+ day, 10+ hour ago (580+ words) UK-based study identifies key patient-centered factors influencing treatment preferences in high-risk NMIBCCULVER CITY, Calif. --(BUSINESS WIRE)--Immunity Bio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced new survey data highlighting the diverse treatment preferences and decision-making priorities of patients…...
Inocras Announces ASCO 2026 Online Publication: Whole-genome HRD phenotyping as a predictor of PARP
2+ day, 1+ hour ago (739+ words) Study conducted with Severance Hospital shows whole-genome sequencing-based HRD phenotyping was associated with longer progression-free survival in patients receiving PARP inhibitor maintenance therapy SAN DIEGO & SEOUL, South Korea--(BUSINESS WIRE)--#Cancer Genome--Inocras, a bioinformatics-led company harnessing the power of…...
SAGA Diagnostics to Present Data on Ultrasensitive Pathlight" MRD Test in Breast, Colon, and Rectal
2+ day, 10+ hour ago (130+ words) MORRISVILLE, N. C. --(BUSINESS WIRE)--#ASCO2026--SAGA Diagnostics, a pioneer in ultrasensitive molecular residual disease (MRD) detection and precision oncology, today announced that the company and key collaborators will present data from three abstracts at the American Society of Clinical Oncology (ASCO) 2026 Annual…...
Pharma Essentia to Present New Clinical Data Supporting the Use of Ropeginterferon Alfa-2b in Essenti
2+ day, 7+ hour ago (425+ words) Title: Association of neutrophil'to'lymphocyte ratio and thrombotic events in US Veterans with Polycythemia vera Abstract Number: 6578 Poster: 371 Presenter: Ying Wang, Ph D Session: Hematologic Malignancies " Leukemia, Myelodysplastic Syndromes, and Allotransplant Date: June 1st Time: 9-12 pm CDT Title: Effect of Higher Initial…...
Securities Fraud Investigation Into Phreesia Inc. (PHR) Announced " Shareholders Who Lost Money Urge
2+ day, 5+ hour ago (330+ words) LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Phreesia Inc. (Phreesia" or the Company") (NYSE: PHR) investors concerning the Company's possible…...
Merck Receives Positive EU CHMP Opinion for KEYTRUDA" (pembrolizumab) Plus Padcev" (enfortumab vedot
2+ day, 9+ hour ago (624+ words) Opinion granted based on positive event-free survival, overall survival and pathologic complete response rate results from the Phase 3 KEYNOTE-905 trial If approved, this combination would become the first and only PD-1 inhibitor plus antibody-drug conjugate regimen for this patient population…...
Schr'dinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2+ day, 9+ hour ago (524+ words) NEW YORK--(BUSINESS WIRE)--Schr'dinger, Inc. (Nasdaq: SDGR) today reported that on May 18, 2026, the company granted (i) a non-statutory stock option to purchase 1, 875 shares of the company's common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect…...
Shopping
Please enter a search for detailed shopping results.